1. Home
  2. HMY vs EXAS Comparison

HMY vs EXAS Comparison

Compare HMY & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Gold Mining Company Limited

HMY

Harmony Gold Mining Company Limited

N/A

Current Price

$19.09

Market Cap

12.7B

ML Signal

N/A

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

N/A

Current Price

$103.47

Market Cap

19.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HMY
EXAS
Founded
1950
1995
Country
South Africa
United States
Employees
34350
N/A
Industry
Precious Metals
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.7B
19.7B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
HMY
EXAS
Price
$19.09
$103.47
Analyst Decision
Buy
Hold
Analyst Count
2
17
Target Price
$16.00
$86.62
AVG Volume (30 Days)
3.9M
1.9M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
0.85%
N/A
EPS Growth
N/A
80.32
EPS
N/A
N/A
Revenue
N/A
$4,144,000.00
Revenue This Year
$40.34
$15.37
Revenue Next Year
$22.08
$12.41
P/E Ratio
$15.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.67
$38.88
52 Week High
$26.04
$103.87

Technical Indicators

Market Signals
Indicator
HMY
EXAS
Relative Strength Index (RSI) 38.99 58.57
Support Level $13.85 $102.95
Resistance Level $19.59 $103.77
Average True Range (ATR) 0.85 0.31
MACD -0.27 -0.07
Stochastic Oscillator 18.18 48.13

Price Performance

Historical Comparison
HMY
EXAS

About HMY Harmony Gold Mining Company Limited

Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: